179
Participants
Start Date
July 30, 2020
Primary Completion Date
December 29, 2025
Study Completion Date
December 29, 2025
Ocrelizumab
Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
Centro Internacional De Mercadeo, Guaynabo
Weill Cornell Medical College, New York
SUNY Upstate Medical Center, Syracuse
Jefferson University Hospitals, Thomas Jefferson University, Philadelphia
Georgetown University Medical Center, Washington D.C.
Johns Hopkins University Neurology Research Office, Baltimore
Multiple Sclerosis Center of Tidewater, Norfolk
Guilford Neurologic Associates, Greensboro
Shepherd Center Inc., Atlanta
Atlanta Neuroscience Institute, Atlanta
Baptist Neurology - Beaches, Jacksonville Beach
University of Miami Miller School of Medicine, Miami
Vanderbilt University Medical Center, Nashville
Neurology Clinic - Cordova, Cordova
Neurology Specialists, Inc, Dayton
Josephson Wallack Munshower Neurology PC, Indianapolis
Wayne State University, Detroit
Wheaton Franciscan Healthcare - St. Francis Outpatient Center, Milwaukee
Medical College of Wisconsin, Milwaukee
University of Chicago, Chicago
Washington University School of Medicine, St Louis
North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic, Frisco
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine Medical Center, Houston
Barrow Neurological Institute, Phoenix
Center for Neurology and Spine - Phoenix - Hunt - PPDS, Phoenix
Swedish Neuroscience Institute, Seattle
Keck School of Medicine of USC, Los Angeles
Rush University Medical Center, Chicago
University of Maryland Medical Center, Baltimore
Hackensack University Medical Center, Hackensack
Aga Khan University Hospital, Nairobi
Lead Sponsor
Genentech, Inc.
INDUSTRY